Reuters logo
BRIEF-Cardiovascular risk for Novo nordisk's degludec insulin uncertain: chair of FDA panel
November 8, 2012 / 7:53 PM / 5 years ago

BRIEF-Cardiovascular risk for Novo nordisk's degludec insulin uncertain: chair of FDA panel

Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel acting chairperson says panel members generally agree that signal of cardiovascular risk was seen for Novo nordisk’s

degludec insulin, and that it “may or may not be real” risk

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below